Patents Assigned to Starpharma Pty Ltd.
  • Patent number: 10265409
    Abstract: A macromolecule includes i) a dendrimer with a core and at least one generation of lysine residue building units, the outermost generation of building units having surface amino groups, ii) a first terminal group covalently attached to a first surface amino group of a building unit, which includes a residue of docetaxel (DTX), and iii) a second terminal group covalently attached to a second surface amino group of a building unit, which includes a pharmacokinetic modifying agent. The pharmacokinetic modifying agent can be a polyethylene glycol (PEG). The first terminal group can be covalently attached to the surface amino group of the dendrimer through a diacid linker. The diacid linker can include a 2,2?-thiodiacetic acid residue. The diacid linker can form an ester bond with a hydroxyl group of the DTX and an amide bond with the surface amino group. A pharmaceutically acceptable salt of the macromolecule can be prepared.
    Type: Grant
    Filed: August 28, 2017
    Date of Patent: April 23, 2019
    Assignee: STARPHARMA PTY LTD
    Inventors: David Owen, Brian Devlin Kelly, Peter Karellas
  • Patent number: 9744246
    Abstract: The present invention relates to a macromolecule comprising a dendrimer having surface amino groups to which at least two different terminal groups are attached including a pharmaceutically active agent and a pharmacokinetic modifying agent, the pharmaceutically active agent comprising a hydroxyl group and being attached to the surface amino group of the dendrimer through a diacid linker. Pharmaceutical compositions comprising the macromolecules and methods of treatment using the macromolecules are also described.
    Type: Grant
    Filed: June 6, 2012
    Date of Patent: August 29, 2017
    Assignee: STARPHARMA PTY LTD
    Inventors: David Owen, Brian Devlin Kelly, Peter Karellas
  • Patent number: 9585387
    Abstract: PEHAM dendrimers of the formula: Specific PEHAM dendrimers are used in a formulation with an active agent for agricultural purposes. In particular, the PEHAM dendrimers may be used for increasing the efficacy of the active agent in various ways, such as by improving solubility of the active agent in the formulation, by improving adhesion and penetration of the active agent to plant surfaces, or by improving the water-fastness of the active agent to the plant or seed. The PEHAM dendrimers may also increase the efficacy of the active agent by increasing soil penetration of the active agent to reach the plant roots or under soil parts, by reducing soil adhesion of the active agent to reach the plant roots or under soil parts, or by reducing enzymatic degradation of the active agent by the plant or seed or microorganisms in the soil.
    Type: Grant
    Filed: February 16, 2015
    Date of Patent: March 7, 2017
    Assignee: STARPHARMA PTY LTD
    Inventors: Ryan T. Hayes, David James Owen, Abhay Singh Chauhan, Veera Reddy Pulgam, Harsh Vardhan
  • Patent number: 9127130
    Abstract: The present invention relates generally to branched macromolecules and their use as imaging or contrast agents. In particular, the invention relates to dendrimers, derived from lysine or lysine analogs, bearing a plurality of functional moieties and their application to imaging techniques in which a disease state may be imaged with a targeted contrast agent.
    Type: Grant
    Filed: August 10, 2007
    Date of Patent: September 8, 2015
    Assignees: STARPHARMA PTY LTD., BAKER IDI HEART AND DIABETES INSTITUTE HOLDINGS LTD
    Inventors: Guy Yeoman Krippner, Zemin Wu, Karlheinz Peter, Christoph Hagemeyer, David Owen
  • Publication number: 20140171375
    Abstract: The present invention relates to a macromolecule comprising a dendrimer having surface amino groups to which at least two different terminal groups are attached including a pharmaceutically active agent and a pharmacokinetic modifying agent, the pharmaceutically active agent comprising a hydroxyl group and being attached to the surface amino group of the dendrimer through a diacid linker. Pharmaceutical compositions comprising the macromolecules and methods of treatment using the macromolecules are also described.
    Type: Application
    Filed: June 6, 2012
    Publication date: June 19, 2014
    Applicant: STARPHARMA PTY LTD
    Inventors: David Owen, Brian Devlin Kelly, Peter Karellas
  • Publication number: 20130116432
    Abstract: The present invention relates to a macromolecule having a controlled terminal group stoichiometry, the macromolecule including a surface layer, at least one subsurface layer and at least two terminal groups including: a first terminal group which is a residue of a pharmaceutically active agent, a derivative thereof or precursor therefor; and a second terminal group selected to modify the pharmacokinetics of the pharmaceutically active agent and/or macromolecule, wherein terminal group stoichiometry refers to the number and type of terminal groups.
    Type: Application
    Filed: December 21, 2012
    Publication date: May 9, 2013
    Applicant: STARPHARMA PTY LTD
    Inventor: Starpharma Pty Ltd
  • Patent number: 8420067
    Abstract: The present invention relates generally to branched macromolecules bearing functional moieties. In particular, the invention relates to dendrimers, derived from lysine or lysine analogues, bearing a plurality of functional moieties. The invention further relates to the use of such macromolecules, particularly in therapeutic applications, and compositions comprising them.
    Type: Grant
    Filed: August 10, 2007
    Date of Patent: April 16, 2013
    Assignee: Starpharma Pty Ltd
    Inventors: Guy Yeoman Krippner, Charlotte Claire Williams, Brian Devlin Kelly, Scott Andrew Henderson, Zemin Wu, Pasquale Razzino
  • Patent number: 8158575
    Abstract: Use of a polylysine, polyamidoamine or polypropylenimine dendrimer having naphthyl disulphonate terminal groups as a topically applied agent in prophylaxis or treatment of sexually transmitted diseases.
    Type: Grant
    Filed: July 6, 2009
    Date of Patent: April 17, 2012
    Assignee: Starpharma Pty., Ltd
    Inventors: Barry Ross Matthews, George Holan, Peter Karellas, Scott Andrew Henderson, David Francis O'Keefe
  • Publication number: 20110230348
    Abstract: Specific PEHAM dendrimers are used in a formulation with an active agent for agricultural purposes, particularly for increasing the efficacy of the active agent in various ways, such as by improving solubility of the active agent in the formulation, by improving adhesion and penetration of the active agent to plant surfaces, by improving the water-fastness of the active agent to the plant or seed, by increasing soil penetration of the active agent to reach the plant roots or under soil parts, or by reducing soil adhesion of the active agent to reach the plant roots or under soil parts, or reducing enzymatic degradation of the active agent by the plant or seed or microorganisms in the soil.
    Type: Application
    Filed: May 4, 2011
    Publication date: September 22, 2011
    Applicants: Dendritic Nanotechnologies, Inc., Starpharma Pty Ltd
    Inventors: Ryan T. Hayes, David James Owen, Abhay Singh Chauhan, Veera Reddy Pulgam
  • Publication number: 20100324146
    Abstract: The present invention relates generally to the use of dendrimer compounds bearing anionic surface groups as inhibitors of hyaluronidase and their use in the treatment of diseases and conditions in which excessive, abnormal or unwanted levels of hyaluronidase are involved or implicated, or in the treatment of diseases or conditions in which the presence or administration of hyaluronic acid is therapeutically effective. The present invention also relates to pharmaceutical compositions and methods for the treatment of such diseases and conditions.
    Type: Application
    Filed: February 20, 2009
    Publication date: December 23, 2010
    Applicant: Starpharma Pty Ltd
    Inventor: Jacinth Kincaid Fairley
  • Publication number: 20100292148
    Abstract: The present invention relates generally to branched macromolecules bearing functional moieties. In particular, the invention relates to dendrimers, derived from lysine or lysine analogues, bearing a plurality of functional moieties. The invention further relates to the use of such macromolecules, particularly in therapeutic applications, and compositions comprising them.
    Type: Application
    Filed: August 10, 2007
    Publication date: November 18, 2010
    Applicant: STARPHARMA PTY LTD.
    Inventors: Guy Yeoman Krippner, Charlotte Claire Williams, Brian Devlin Kelly, Scott Andrew Henderson, Zemin Wu, Pasquale Razzino
  • Publication number: 20100278750
    Abstract: The present invention relates generally to branched macromolecules and their use as imaging or contrast agents. In particular, the invention relates to dendrimers, derived from lysine or lysine analogues, bearing a plurality of functional moieties and their application to imaging techniques in which a disease state may be imaged with a targeted contrast agent.
    Type: Application
    Filed: August 10, 2007
    Publication date: November 4, 2010
    Applicants: STARPHARMA PTY LTD, BAKER MEDICAL RESEARCH INSTITUTE
    Inventors: Guy Yeoman Krippner, Zemin Wu, Karlheinz Peter, Christoph Hagemeyer, David Owen
  • Publication number: 20090324535
    Abstract: The present invention relates to a macromolecule having a controlled terminal group stoichiometry, the macromolecule including a surface layer, at least one subsurface layer and at least two terminal groups including: a first terminal group which is a residue of a pharmaceutically active agent, a derivative thereof or precursor therefor; and a second terminal group selected to modify the pharmacokinetics of the pharmaceutically active agent and/or macromolecule, wherein terminal group stoichiometry refers to the number and type of terminal groups.
    Type: Application
    Filed: May 15, 2006
    Publication date: December 31, 2009
    Applicant: Starpharma Pty Ltd
    Inventors: Benjamin James Boyd, Lisa Michelle Kaminskas, Christopher John Hamilton Porter, Peter Karellas, Guy Yeoman Krippner, Pasquale Razzino, Brian Devlin Kelly, Zemin Wu, Sue Pallich
  • Patent number: 7589056
    Abstract: Use of a polylysine, polyamidoamine or polypropylenimine dendrimer having naphthyl disulphonate terminal groups as a topically applied agent in prophylaxis or treatment of sexually transmitted diseases.
    Type: Grant
    Filed: March 28, 2002
    Date of Patent: September 15, 2009
    Assignee: Starpharma Pty. Ltd.
    Inventors: Barry Ross Matthews, George Holan, Peter Karellas, Scott Andrew Henderson, David Francis O'Keefe
  • Patent number: 7572459
    Abstract: To inhibit, prophylactically or therapeutically, a bacterial, yeast, fungal, or parasitic agent in a patient, an effective amount of a dendrimer is administered to the patient, which dendrimer has a plurality of terminal groups, at least one of which has an anionic- or cationic-moiety covalently bonded or linked thereto. The anionic-containing moiety is not a disaccharide or oligosaccharide moiety, and, where the anionic-containing moiety is a neuraminic- or sialic acid-containing moiety, it is modified in the 4-position by substitution with an amino, amido, cyano, azido or guanido group, or is unsaturated.
    Type: Grant
    Filed: August 26, 2002
    Date of Patent: August 11, 2009
    Assignee: Starpharma Pty Ltd.
    Inventors: Barry Ross Matthews, George Holan